Bendamustine has been evaluated in numerous clinical trials spanning Early Phase 1 through Phase 4, focusing on hematologic malignancies and lymphoproliferative disorders including chronic lymphocytic leukemia, multiple myeloma, follicular lymphoma, diffuse large B-cell lymphoma, and primary central nervous system lymphoma. Sponsored by academic institutions and pharmaceutical companies, these investigations encompass various recruitment statuses, including active, completed, terminated, and withdrawn protocols. Overall, this broad trial landscape underscores the extensive clinical evaluation of bendamustine as both monotherapy and in combination regimens across diverse hematological indications.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06191887 | RECRUITING | B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia |
Mayo Clinic |
2024-03-18 | PHASE1 |
| NCT06191744 | ACTIVE_NOT_RECRUITING | Follicular Lymphoma (FL) |
Genmab |
2024-02-05 | PHASE3 |
| NCT07634471 | RECRUITING | Follicular Lymphoma |
Merck Sharp & Dohme LLC |
2026-06-22 | PHASE2; PHASE3 |
| NCT06313996 | WITHDRAWN | Relapsed or Refractory Follicular Lymphoma |
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
2024-03-29 | PHASE3 |
| NCT06205290 | WITHDRAWN | Leukemia, Lymphocytic, Chronic, B-Cell |
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
2024-01-16 | PHASE3 |
| NCT06363994 | RECRUITING | Mantle Cell Lymphoma |
InnoCare Pharma Inc. |
2024-05-29 | PHASE3 |
| NCT07753369 | NOT_YET_RECRUITING | Small Lymphocytic Lymppho; Relapsed/Refractory Chronic Lymphocytic Leukemia |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2026-08 | PHASE3 |
| NCT06961500 | NOT_YET_RECRUITING | Follicular Lymphoma Grade 3A |
Sun Yat-sen University |
2025-05-01 | PHASE2 |
| NCT05371093 | ACTIVE_NOT_RECRUITING | Relapsed/Refractory Follicular Lymphoma |
Kite, A Gilead Company |
2022-09-22 | PHASE3 |
| NCT07225985 | RECRUITING | Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma |
Fred Hutchinson Cancer Center |
2026-04-27 | PHASE1; PHASE2 |
| NCT04849715 | WITHDRAWN | Mantle Cell Lymphoma |
Incyte Corporation |
2022-03-11 | PHASE3 |
| NCT07719855 | NOT_YET_RECRUITING | Follicular Lymphoma ( FL) |
Ruijin Hospital |
2026-07 | PHASE3 |
| NCT05245656 | RECRUITING | Mantle Cell Lymphoma |
Kim, Seok Jin |
2022-10-18 | PHASE2 |
| NCT06970743 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
BeOne Medicines |
2025-05-29 | PHASE3 |
| NCT06854003 | RECRUITING | Mantle Cell Lymphoma; Lymphoma |
Christine Ryan |
2025-04-22 | PHASE2 |
| NCT07072221 | RECRUITING | Peripheral T-cell Lymphoma |
The First Affiliated Hospital of Soochow University |
2024-11-01 | |
| NCT05848765 | RECRUITING | Relapsed Follicular Lymphoma; Refractory Follicular Lymphoma |
University of Birmingham |
2023-09-04 | PHASE2 |
| NCT06241456 | RECRUITING | Advanced Solid Tumor |
Fate Therapeutics |
2024-01-05 | PHASE1 |
| NCT07593482 | NOT_YET_RECRUITING | B-cell Lymphoma |
Swiss Cancer Institute |
2026-09 | PHASE2 |
| NCT07139873 | RECRUITING | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
Dizal Pharmaceuticals |
2025-09-08 | PHASE3 |
| NCT06483048 | RECRUITING | Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Fallopian Tube Carcinosarcoma; Recurrent Female Reproductive System Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Carcinosarcoma; Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Carcinosarcoma; Refractory Fallopian Tube Carcinoma; Refractory Female Reproductive System Carcinoma; Refractory Ovarian Carcinoma; Refractory Primary Peritoneal Carcinoma |
Mayo Clinic |
2024-09-20 | PHASE1 |
| NCT07169565 | NOT_YET_RECRUITING | Waldenström Macroglobulinemia (WM) |
Institute of Hematology & Blood Diseases Hospital, China |
2025-09-01 | PHASE1 |
| NCT07725406 | NOT_YET_RECRUITING | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed or Refractory Multiple Myeloma (MM) |
Weill Medical College of Cornell University |
2026-08-01 | PHASE1 |
| NCT07477639 | RECRUITING | Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis (SPMS); Multiple Sclerosis; Multiple Sclerosis (MS) Primary Progressive; Multiple Sclerosis (MS) Secondary Progressive |
Tr1X, Inc. |
2026-03 | PHASE1; PHASE2 |
| NCT07126678 | RECRUITING | Follicular Lymphoma; Treatment Naive |
The First Affiliated Hospital with Nanjing Medical University |
2025-07-15 | |
| NCT05058404 | ACTIVE_NOT_RECRUITING | Follicular Lymphoma |
Fondazione Italiana Linfomi - ETS |
2021-12-01 | PHASE3 |
| NCT07259122 | NOT_YET_RECRUITING | Waldenström Macroglobulinemia (WM) |
Institute of Hematology & Blood Diseases Hospital, China |
2025-12-30 | PHASE2 |
| NCT05711628 | WITHDRAWN | Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma |
National Cancer Institute (NCI) |
2023-08-10 | PHASE3 |
| NCT07208981 | RECRUITING | Marginal Zone Lymphoma(MZL) |
The First Affiliated Hospital with Nanjing Medical University |
2025-08-14 | PHASE2 |
| NCT06477549 | RECRUITING | Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Biphenotypic Acute Leukemia; Lymphoblastic Lymphoma; Myeloproliferative Neoplasm; Myelodysplastic Syndromes |
St. Petersburg State Pavlov Medical University |
2024-06-21 | PHASE2 |
| NCT06846671 | RECRUITING | CLL; Chronic Lymphocytic Leukemia |
BeOne Medicines |
2025-04-10 | PHASE3 |
| NCT06911502 | RECRUITING | Follicular Lymphoma |
Celgene |
2025-07-28 | PHASE3 |
| NCT04892277 | RECRUITING | Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia |
Mayo Clinic |
2022-10-03 | PHASE1 |
| NCT04223765 | RECRUITING | Mantle Cell Lymphoma; Follicular Lymphoma; Splenic Marginal Zone Lymphoma; Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Nodal Marginal Zone Lymphoma; Indolent Non-hodgkin Lymphoma |
UNC Lineberger Comprehensive Cancer Center |
2020-11-12 | PHASE1 |
| NCT06094842 | WITHDRAWN | Prostate Carcinoma; Prostate Small Cell Neuroendocrine Carcinoma; Stage III Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8 |
Fred Hutchinson Cancer Center |
2025-04-15 | PHASE1 |
| NCT04083495 | RECRUITING | Peripheral T Cell Lymphoma |
UNC Lineberger Comprehensive Cancer Center |
2019-09-17 | PHASE2 |
| NCT06091254 | RECRUITING | Follicular Lymphoma (FL) |
Regeneron Pharmaceuticals |
2023-12-12 | PHASE3 |
| NCT06757894 | NOT_YET_RECRUITING | Follicular Lymphoma (FL) |
Sun Yat-sen University |
2025-02-01 | PHASE2 |
| NCT06522737 | RECRUITING | Lymphoma |
SecuraBio |
2025-05-19 | PHASE3 |
| NCT06043713 | RECRUITING | Metastatic Malignant Solid Neoplasm |
Fred Hutchinson Cancer Center |
2023-12-15 | PHASE1 |
| NCT07189065 | RECRUITING | Diffuse Large B-Cell Lymphoma (DLBCL) |
Guangzhou Lupeng Pharmaceutical Company LTD. |
2025-11-27 | PHASE2 |
| NCT04587687 | RECRUITING | Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma |
University of California, Davis |
2020-12-04 | PHASE2 |
| NCT07206264 | NOT_YET_RECRUITING | Mantle Cell Lymphoma |
Tianjin Medical University Cancer Institute and Hospital |
2025-10 | PHASE2 |
| NCT06136351 | RECRUITING | Lymphoma, Mantle-Cell |
Ruijin Hospital |
2023-11-15 | PHASE2 |
| NCT06308978 | RECRUITING | Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV); Idiopathic Inflammatory Myositis (IIM); Systemic Sclerosis (SSc); Systemic Lupus Erythematosus (SLE); Lupus Nephritis |
Fate Therapeutics |
2024-03-28 | PHASE1 |
| NCT04663347 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma; Follicular Lymphoma |
Genmab |
2020-11-03 | PHASE1; PHASE2 |
| NCT06557330 | NOT_YET_RECRUITING | Lymphoma; Indolent Non-hodgkin Lymphoma |
Fox Chase Cancer Center |
2025-06 | PHASE2 |
| NCT05139017 | RECRUITING | DLBCL; Diffuse Large B-Cell Lymphoma |
Merck Sharp & Dohme LLC |
2022-01-14 | PHASE2; PHASE3 |
| NCT05451771 | ACTIVE_NOT_RECRUITING | AL Amyloidosis |
Columbia University |
2022-10-26 | PHASE1; PHASE2 |
| NCT06006117 | RECRUITING | Marginal Zone Lymphoma |
The Lymphoma Academic Research Organisation |
2023-09-05 | PHASE3 |
| NCT06084936 | RECRUITING | Lymphoma |
Hoffmann-La Roche |
2023-10-22 | PHASE3 |
| NCT04022239 | RECRUITING | Hematopoietic and Lymphoid System Neoplasm |
M.D. Anderson Cancer Center |
2020-03-13 | PHASE1; PHASE2 |
| NCT06496308 | RECRUITING | Mantle Cell Lymphoma (MCL) |
Ruijin Hospital |
2024-07-10 | PHASE3 |
| NCT06504940 | RECRUITING | Marginal Zone Lymphoma |
First Affiliated Hospital of Zhejiang University |
2024-06-28 | PHASE2 |
| NCT07008053 | NOT_YET_RECRUITING | Marginal Zone Lymphomas |
Tianjin Medical University Cancer Institute and Hospital |
2025-07 | PHASE2 |
| NCT07003464 | NOT_YET_RECRUITING | Chronic Lymphocytic Leukemia |
The First Hospital of Jilin University |
2025-06-15 | PHASE2 |
| NCT05868395 | RECRUITING | Mantle-cell Lymphoma |
Medical University of Vienna |
2024-01-02 | PHASE2 |
| NCT05624554 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Merck Sharp & Dohme LLC |
2023-03-16 | PHASE3 |
| NCT06532084 | RECRUITING | Acute Myeloid Leukemia, in Relapse; Myelodysplastic Syndromes; Chronic Myeloid Leukemia; Myeloproliferative Neoplasm |
St. Petersburg State Pavlov Medical University |
2024-05-22 | PHASE2 |
| NCT06942507 | NOT_YET_RECRUITING | Waldenström's Macroglobulinemia (WM) |
Peking Union Medical College Hospital |
2025-05-01 | |
| NCT04002297 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma |
BeOne Medicines |
2019-08-20 | PHASE3 |
| NCT05249959 | ACTIVE_NOT_RECRUITING | Relapsed Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma |
Fondazione Italiana Linfomi - ETS |
2022-03-21 | PHASE2 |
| NCT02972840 | ACTIVE_NOT_RECRUITING | Lymphoma, Mantle Cell |
Acerta Pharma BV |
2017-04-05 | PHASE3 |
| NCT04515238 | ACTIVE_NOT_RECRUITING | Chronic Lymphoid Leukemia |
German CLL Study Group |
2020-10-01 | PHASE2 |
| NCT03755804 | ACTIVE_NOT_RECRUITING | Hodgkin Lymphoma |
St. Jude Children's Research Hospital |
2018-12-12 | PHASE2 |
| NCT04792489 | RECRUITING | Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma; High Grade B-cell Lymphoma (HGBCL); Primary Mediastinal B-cell Lymphoma (PMBCL); Transformed Lymphoma; Central Nervous System Lymphoma; Mantle Cell Lymphoma (MCL); Richter Transformation; Transplant-ineligible 2nd Line DLBCL |
Miltenyi Biomedicine GmbH |
2021-05-25 | PHASE2 |
| NCT04115631 | ACTIVE_NOT_RECRUITING | Liver Lymphoma; Mantle Cell Lymphoma |
ECOG-ACRIN Cancer Research Group |
2019-12-13 | PHASE2 |
| NCT01479842 | ACTIVE_NOT_RECRUITING | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia |
Kami Maddocks, MD |
2014-03-26 | PHASE1 |
| NCT06561347 | RECRUITING | Waldenstrom Macroglobulinemia |
Massachusetts General Hospital |
2024-12-20 | PHASE2 |
| NCT04510636 | RECRUITING | Classical Hodgkin Lymphoma; Relapsed Cancer; Refractory Cancer |
University Health Network, Toronto |
2021-12-20 | PHASE2 |
| NCT03352765 | ACTIVE_NOT_RECRUITING | Lymphoma |
Memorial Sloan Kettering Cancer Center |
2017-11-20 | PHASE1 |
| NCT02153580 | ACTIVE_NOT_RECRUITING | B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; B-Cell Prolymphocytic Leukemia; High Grade B-Cell Lymphoma, Not Otherwise Specified; Post-Transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Hairy Cell Leukemia; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma |
City of Hope Medical Center |
2014-09-24 | PHASE1 |
| NCT06563778 | NOT_YET_RECRUITING | Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma |
Chinese PLA General Hospital |
2024-09-01 | PHASE2 |
| NCT06554600 | RECRUITING | Refractory or Relapsed Diffuse Large B Cell Lymphoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2024-08-31 | PHASE2 |
| NCT04913103 | NOT_YET_RECRUITING | Lymphoma, Mantle-Cell |
Czech Lymphoma Study Group |
2021-09-01 | PHASE2 |
| NCT06425302 | ACTIVE_NOT_RECRUITING | Lymphoma, Follicular |
Celgene |
2024-08-30 | PHASE2 |
| NCT06931613 | ENROLLING_BY_INVITATION | Relapsed or Refractory Hodgkin Lymphoma; Children; Nivolumab; Autologous Haemopoietic Stem Cell Transplant |
St. Petersburg State Pavlov Medical University |
2022-06-01 | PHASE2 |
| NCT06465446 | NOT_YET_RECRUITING | Classic Hodgkin Lymphoma |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
2024-06 | PHASE3 |
| NCT05934097 | WITHDRAWN | Diffuse Large B Cell Lymphoma; Transformed Indolent Non-Hodgkin's Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma |
Fate Therapeutics |
2022-12 | PHASE1 |
| NCT05551936 | ACTIVE_NOT_RECRUITING | Follicular Lymphoma |
Vaishalee Kenkre |
2023-01-26 | PHASE1; PHASE2 |
| NCT04882163 | WITHDRAWN | Lymphoma, B-Cell |
Celgene |
2021-10-10 | PHASE1; PHASE2 |
| NCT03609593 | COMPLETED | Chronic Lymphocytic Leukemia |
Nicole Lamanna |
2018-11-12 | PHASE2 |
| NCT03269669 | ACTIVE_NOT_RECRUITING | Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma |
National Cancer Institute (NCI) |
2018-01-23 | PHASE2 |
| NCT04624906 | ACTIVE_NOT_RECRUITING | Waldenstrom Macroglobulinemia |
Sunnybrook Health Sciences Centre |
2021-03-02 | PHASE2 |
| NCT04674813 | COMPLETED | Multiple Myeloma |
Juno Therapeutics, a Subsidiary of Celgene |
2021-02-24 | PHASE1 |
| NCT06761911 | NOT_YET_RECRUITING | Hodgkin Lymphoma (Category) |
Xiuhua Sun |
2024-12-31 | PHASE4 |
| NCT03602157 | ACTIVE_NOT_RECRUITING | Lymphoma; Immune System Diseases; Immunoproliferative Disorders; Lymphatic Diseases; Lymphoproliferative Disorders; Neoplasms; Cutaneous Lymphoma; Cutaneous Anaplastic Large Cell Lymphoma; Mycosis Fungoides; Sezary Syndrome; Lymphomatoid Papulosis; Cutaneous T Cell Lymphoma; Gray Zone Lymphoma |
UNC Lineberger Comprehensive Cancer Center |
2018-10-29 | PHASE1 |
| NCT05352828 | ACTIVE_NOT_RECRUITING | Classical Hodgkin Lymphoma; Hodgkin Disease Refractory; Hodgkin Disease Recurrent |
Tessa Therapeutics |
2022-07-25 | PHASE1 |
| NCT04607772 | WITHDRAWN | Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
Karyopharm Therapeutics Inc |
2020-11-18 | PHASE1; PHASE2 |
| NCT03856216 | TERMINATED | Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia; Lymphocytic Neoplasm; Lymphoma |
M.D. Anderson Cancer Center |
2019-10-28 | PHASE2 |
| NCT04673617 | COMPLETED | Non Hodgkin Lymphoma |
Artiva Biotherapeutics, Inc. |
2021-03-29 | PHASE1; PHASE2 |
| NCT05508867 | COMPLETED | Hodgkin Lymphoma |
Merck Sharp & Dohme LLC |
2022-10-18 | PHASE2 |
| NCT03696784 | ACTIVE_NOT_RECRUITING | Lymphoma; Lymphoma, B-Cell; Immune System Diseases; Immunoproliferative Disorders; Lymphatic Diseases |
UNC Lineberger Comprehensive Cancer Center |
2019-03-12 | PHASE1 |
| NCT02996773 | COMPLETED | Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Myelodysplastic Syndromes; Chronic Myelogenous Leukemia; Lymphoma,Non-Hodgkin; Lymphoma, Hodgkin; Lymphoma, Follicular; Marginal Zone Lymphoma; Large Cell Lymphoma; Mantle-Cell Lymphoma; Gray Zone Lymphoma; Burkitt Lymphoma; High Risk Undifferentiated Acute Leukemia |
University of Arizona |
2016-11-29 | PHASE1 |
| NCT05023980 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Loxo Oncology, Inc. |
2021-09-23 | PHASE3 |
| NCT04629729 | ACTIVE_NOT_RECRUITING | Lymphoma, B-Cell; Chronic Lymphocytic Leukemia; Precursor B-Cell Acute Lymphoblastic Leukemia |
Fate Therapeutics |
2021-07-12 | PHASE1 |
| NCT05950334 | COMPLETED | Relapsed/Refractory B-Cell Lymphoma |
Fate Therapeutics |
2023-11-16 | PHASE1 |
| NCT06170489 | RECRUITING | Hodgkin Lymphoma |
Shanghai Junshi Bioscience Co., Ltd. |
2023-12-28 | PHASE3 |
| NCT04268706 | ACTIVE_NOT_RECRUITING | Hodgkin Lymphoma, Adult; Hodgkin Disease Recurrent; Hodgkin Disease Refractory; Hodgkin Disease, Pediatric |
Tessa Therapeutics |
2021-02-01 | PHASE2 |
| NCT05979948 | UNKNOWN | Waldenström's Macroglobulinemia |
Shanghai Changzheng Hospital |
2023-08-01 | PHASE2 |
| NCT04049825 | COMPLETED | Relapsed or Refractory Diffuse Large B-cell Lymphoma |
Otsuka Pharmaceutical Co., Ltd. |
2019-11-22 | PHASE1 |
| NCT05914662 | UNKNOWN | Waldenstrom Macroglobulinemia |
Institute of Hematology & Blood Diseases Hospital, China |
2023-02-15 | PHASE2 |
| NCT05660993 | UNKNOWN | Hodgkin Lymphoma |
National Research Center for Hematology, Russia |
2019-08-19 | PHASE2 |
| NCT04433182 | TERMINATED | Diffuse Large B-cell Lymphoma |
Fondazione Italiana Linfomi - ETS |
2020-08-18 | PHASE2 |
| NCT02401503 | COMPLETED | Chronic Lymphocytic Leucemia |
German CLL Study Group |
2015-05-06 | PHASE2 |
| NCT06415708 | UNKNOWN | B Cell Lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
2023-11-30 | PHASE2 |
| NCT03615664 | COMPLETED | Hodgkin's Lymphoma |
Polish Lymphoma Research Group |
2017-11-06 | PHASE2 |
| NCT03997968 | COMPLETED | Malignancy; Non-hodgkin Lymphoma; Multiple Myeloma; Breast Cancer; Ovarian Cancer; Soft Tissue Sarcoma; Head and Neck Cancer; DLBCL; Mantle Cell Lymphoma; Follicular Lymphoma; Pancreatic Cancer; CLL; Small Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer |
Cyteir Therapeutics, Inc. |
2019-10-09 | PHASE1; PHASE2 |
| NCT07450508 | COMPLETED | Classical Hodgkin Lymphoma Relapsed |
Cairo University |
2024-04-30 | PHASE3 |
| NCT04809766 | TERMINATED | Metastatic Pancreatic Ductal Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8 |
Fred Hutchinson Cancer Center |
2021-12-14 | PHASE1 |
| NCT05182073 | COMPLETED | Multiple Myeloma; Myeloma |
Fate Therapeutics |
2021-11-10 | PHASE1 |
| NCT04943302 | WITHDRAWN | Amyloidosis; Light Chain (AL) Amyloidosis |
Tufts Medical Center |
2022-09-01 | PHASE2 |
| NCT05287984 | UNKNOWN | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Newly Diagnosed |
Institute of Hematology & Blood Diseases Hospital, China |
2022-03-22 | PHASE2 |
| NCT02763319 | COMPLETED | Diffuse Large B-cell Lymphoma |
Incyte Corporation |
2016-11-28 | PHASE2; PHASE3 |
| NCT04943757 | COMPLETED | Myeloid Leukemia, Acute; Chronic Myeloid Leukemia; Myelodysplastic Syndromes; Myeloproliferative Neoplasm |
St. Petersburg State Pavlov Medical University |
2021-01-21 | PHASE2 |
| NCT02927769 | COMPLETED | Hodgkin Disease |
Bristol-Myers Squibb |
2017-03-28 | PHASE2 |
| NCT04942730 | COMPLETED | Leukemia, Acute Lymphoblastic; Myeloid Leukemia, Acute; Biphenotypic Acute Leukemia; Lymphoblastic Lymphoma; Myelodysplastic Syndromes; Myeloproliferative Neoplasm |
St. Petersburg State Pavlov Medical University |
2021-01-21 | PHASE2 |
| NCT01476787 | COMPLETED | Follicular Lymphoma |
Celgene |
2011-12-29 | PHASE3 |
| NCT04285567 | COMPLETED | Chronic Lymphocytic Leukemia (CLL) |
Hoffmann-La Roche |
2020-05-28 | PHASE3 |
| NCT05757466 | UNKNOWN | Hodgkin Lymphoma |
St. Petersburg State Pavlov Medical University |
2023-04-19 | PHASE2 |
| NCT02950051 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2016-12-13 | PHASE3 |
| NCT03295240 | COMPLETED | Mantle Cell Lymphoma; Lymphoma |
Memorial Sloan Kettering Cancer Center |
2017-09-20 | EARLY_PHASE1 |
| NCT05813132 | COMPLETED | Lymphoma |
Rehab Werida |
2022-11-11 | |
| NCT03739619 | COMPLETED | Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma; Classical Hodgkin Lymphoma; Hodgkin Lymphoma |
Emory University |
2018-11-26 | PHASE1; PHASE2 |
| NCT04023071 | TERMINATED | Acute Myelogenous Leukemia; B-cell Lymphoma |
Fate Therapeutics |
2019-10-04 | PHASE1 |
| NCT04245722 | TERMINATED | Lymphoma, B-Cell; Chronic Lymphocytic Leukemia |
Fate Therapeutics |
2020-03-19 | PHASE1 |
| NCT02626455 | TERMINATED | Lymphoma, Non-Hodgkin |
Bayer |
2016-01-06 | PHASE3 |
| NCT01437709 | COMPLETED | Mantle Cell Lymphoma |
Memorial Sloan Kettering Cancer Center |
2011-09 | PHASE2 |
| NCT04138875 | WITHDRAWN | PTLD; Lymphoid Tumor; Hematopoietic/Lymphoid Cancer; Plasmacytic Hyperplasia PTLD; Infectious Mononucleosis; Florid Follicular Hyperplasia PTLD; Polymorphic PTLD; Monomorphic PTLD; Classical Hodgkin Lymphoma Type PTLD |
Yale University |
2022-01 | PHASE2 |
| NCT04666038 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Loxo Oncology, Inc. |
2021-03-09 | PHASE3 |
| NCT03311126 | TERMINATED | Mantle Cell Lymphoma; Non-hodgkin Lymphoma; Non Hodgkin Lymphoma |
University of Wisconsin, Madison |
2017-09-29 | PHASE2 |
| NCT02348216 | COMPLETED | Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma (TFL); Primary Mediastinal B-cell Lymphoma (PMBCL); High Grade B-cell Lymphoma (HGBCL) |
Kite, A Gilead Company |
2015-04-21 | PHASE1; PHASE2 |
| NCT01664910 | COMPLETED | Hematopoietic and Lymphoid Cell Neoplasm |
M.D. Anderson Cancer Center |
2012-10-29 | PHASE1; PHASE2 |
| NCT05006469 | UNKNOWN | Bendamustine; Multiple Myeloma |
Liao Aijun |
2021-06-01 | PHASE3 |
| NCT04217317 | TERMINATED | Relapsed T-Cell Lymphoma; Refractory T-Cell Lymphoma; Non Hodgkin Lymphoma |
Wake Forest University Health Sciences |
2020-09-16 | PHASE2 |
| NCT01716806 | COMPLETED | Hodgkin Disease; Peripheral T Cell Lymphoma |
Seagen Inc. |
2012-10-31 | PHASE2 |
| NCT04745832 | TERMINATED | Follicular Lymphoma (FL); Non Hodgkin Lymphoma; Marginal Zone Lymphoma |
MEI Pharma, Inc. |
2021-08-13 | PHASE3 |
| NCT04083898 | TERMINATED | Multiple Myeloma |
Washington University School of Medicine |
2020-04-03 | PHASE1 |
| NCT04842318 | UNKNOWN | Follicular Lymphoma |
Ruijin Hospital |
2021-03-01 | PHASE4 |
| NCT01415752 | ACTIVE_NOT_RECRUITING | Lymphoma; Mantle Cell Lymphoma |
Eastern Cooperative Oncology Group |
2012-08-09 | PHASE2 |
| NCT05551936 | Recruiting | Follicular Lymphoma |
Vaishalee Kenkre|Epizyme Inc.|University of Wisconsin Madison|Big Ten Cancer Research Consortium |
2023-01-26 | Phase 1|Phase 2 |
| NCT01059786 | ACTIVE_NOT_RECRUITING | Hairy Cell Leukemia |
National Cancer Institute (NCI) |
2010-07-01 | PHASE2 |
| NCT03834688 | COMPLETED | Mantle Cell Lymphoma |
PrECOG, LLC. |
2020-01-13 | PHASE2 |
| NCT01754857 | COMPLETED | Lymphoid Leukemia; Small Lymphocytic Lymphoma; Lymphoma, Non-Hodgkin |
University of Wisconsin, Madison |
2013-11-12 | PHASE2 |
| NCT03424122 | COMPLETED | B-cell Lymphoma |
Incyte Corporation |
2018-07-02 | PHASE1 |
| NCT02717624 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma (MCL) |
Acerta Pharma BV |
2016-04-20 | PHASE1 |
| NCT03872180 | ACTIVE_NOT_RECRUITING | CCND1 Positive; Mantle Cell Lymphoma; t(11;14) Positive |
Emory University |
2019-04-11 | PHASE2 |
| NCT02793583 | TERMINATED | Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Small Lymphocytic Lymphoma |
TG Therapeutics, Inc. |
2016-05-25 | PHASE2; PHASE3 |
| NCT01974440 | COMPLETED | Lymphoma |
Janssen Research & Development, LLC |
2014-01-31 | PHASE3 |
| NCT03778073 | TERMINATED | B-cell Non Hodgkin Lymphoma; Richter's Transformation |
TG Therapeutics, Inc. |
2019-04-17 | PHASE1 |
| NCT04897477 | UNKNOWN | Non-hodgkin Lymphoma,B Cell |
Chinese PLA General Hospital |
2021-04-22 | PHASE1; PHASE2 |
| NCT04535102 | WITHDRAWN | Diffuse Large B Cell Lymphoma |
University of Colorado, Denver |
2021-01-29 | PHASE2 |
| NCT02445131 | COMPLETED | Chronic Lymphocytic Leucemia |
German CLL Study Group |
2015-05-28 | PHASE2 |
| NCT04762745 | UNKNOWN | Relapsed, Refractory, Multiple Myeloma |
Sun Yat-sen University |
2021-02 | PHASE1; PHASE2 |
| NCT02678299 | UNKNOWN | Malignant Lymphoma |
University of Aarhus |
2016-02 | PHASE1; PHASE2 |
| NCT02063685 | COMPLETED | Follicular Non-Hodgkin's Lymphoma |
Fondazione Italiana Linfomi - ETS |
2012-07 | PHASE3 |
| NCT03492775 | COMPLETED | Indolent Non-hodgkin Lymphoma |
Prof. Dr. Wolfgang Hiddemann |
2017-12-12 | PHASE2 |
| NCT03823365 | UNKNOWN | Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia |
A.O. Ospedale Papa Giovanni XXIII |
2018-12-17 | PHASE1 |
| NCT03524235 | COMPLETED | Multiple Myeloma; CLL; Chronic Lymphocytic Leukemia; Lymphoma; Hodgkin Lymphoma |
Noah Merin |
2018-07-18 | PHASE1 |
| NCT02257567 | COMPLETED | Lymphoma |
Hoffmann-La Roche |
2014-10-15 | PHASE1; PHASE2 |
| NCT03406156 | COMPLETED | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) |
AbbVie |
2018-08-10 | PHASE3 |
| NCT02970318 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia |
Acerta Pharma BV |
2017-02-02 | PHASE3 |
| NCT05023980 | Active not recruiting | Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma |
Loxo Oncology Inc.|Eli Lilly and Company |
2021-09-23 | Phase 3 |
| NCT03567876 | COMPLETED | Lymphoma, Mantle-Cell |
Fondazione Italiana Linfomi - ETS |
2018-09-03 | PHASE2 |
| NCT04236141 | TERMINATED | Diffuse, Large B-Cell, Lymphoma |
Hoffmann-La Roche |
2020-07-10 | PHASE3 |
| NCT01776840 | COMPLETED | Mantle Cell Lymphoma |
Janssen Research & Development, LLC |
2013-05-16 | PHASE3 |
| NCT03336333 | ACTIVE_NOT_RECRUITING | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
BeiGene |
2017-10-31 | PHASE3 |
| NCT03113422 | COMPLETED | Follicular Lymphoma; Non-Hodgkin's Lymphoma Follicular; Non-Hodgkin's Lymphoma, Adult High Grade |
PrECOG, LLC. |
2017-12-27 | PHASE2 |
| NCT02187133 | COMPLETED | Lymphoma, Non-Hodgkin; Lymphoma |
University of California, San Francisco |
2015-05-05 | PHASE1 |
| NCT03039114 | COMPLETED | Lymphoma |
Incyte Corporation |
2017-02-15 | PHASE1 |
| NCT04155840 | TERMINATED | Lymphoid Leukemia; Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
University of Washington |
2020-01-31 | PHASE2 |
| NCT03787264 | COMPLETED | Chronic Lymphoid Leukemia |
German CLL Study Group |
2019-01-14 | PHASE2 |
| NCT03593018 | COMPLETED | Relapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell Lymphoma |
The Lymphoma Academic Research Organisation |
2018-11-09 | PHASE3 |
| NCT02095834 | COMPLETED | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
M.D. Anderson Cancer Center |
2014-04-24 | PHASE1 |
| NCT01234766 | COMPLETED | Lymphoma, Follicular |
Dartmouth-Hitchcock Medical Center |
2010-10 | PHASE2 |
| NCT03315520 | UNKNOWN | Relapsed/Refractory Malignant Lymphomas |
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia |
2016-01-22 | PHASE2 |
| NCT02853370 | COMPLETED | Marginal Zone B-cell Lymphoma |
International Extranodal Lymphoma Study Group (IELSG) |
2012-07 | PHASE2 |
| NCT02799147 | COMPLETED | Leukemia, Acute Lymphoblastic; Acute Myeloid Leukemia; Mixed-Lineage Acute Leukemias |
St. Petersburg State Pavlov Medical University |
2016-06 | PHASE1; PHASE2 |
| NCT03604679 | COMPLETED | Advanced Solid Tumor |
SymBio Pharmaceuticals |
2018-05-24 | PHASE1 |
| NCT03900377 | COMPLETED | Lymphoma, B-cell, Diffuse |
SymBio Pharmaceuticals |
2019-04-01 | PHASE1; PHASE2 |
| NCT02257242 | COMPLETED | Lymphoma, Non-Hodgkin; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Small-Cell; Waldenstrom Macroglobulinemia; Lymphoma, B-Cell, Marginal Zone |
Brown University |
2017-05-10 | PHASE1 |
| NCT03817853 | COMPLETED | Advanced Follicular Lymphoma |
Hoffmann-La Roche |
2019-02-26 | PHASE4 |
| NCT02954406 | TERMINATED | Lymphoma, Non-Hodgkin |
Millennium Pharmaceuticals, Inc. |
2017-03-05 | PHASE1 |
| NCT01594229 | COMPLETED | Non-Hodgkin's Lymphoma |
AbbVie |
2012-05-21 | PHASE1 |
| NCT02747732 | UNKNOWN | Diffuse Large B Cell Lymphoma; Primary Mediastinal (Thymic) Large B-cell Lymphoma; Transformed Indolent Lymphoma; Recurrent Disease; Refractory Cancer |
Meirav Kedmi MD |
2016-12 | PHASE2 |
| NCT02424851 | COMPLETED | Multiple Myeloma; Chronic Kidney Disease |
Oxford University Hospitals NHS Trust |
2014-11 | PHASE2 |
| NCT02416206 | COMPLETED | Multiple Myeloma |
Northside Hospital, Inc. |
2015-04-27 | PHASE2 |
| NCT03187223 | COMPLETED | Multiple Myeloma |
Insel Gruppe AG, University Hospital Bern |
2017-07-20 | PHASE2 |
| NCT01644253 | TERMINATED | Chronic Lymphocytic Leukemia; Peripheral T-cell Lymphoma |
Aptevo Therapeutics |
2012-09 | PHASE1 |
| NCT03623373 | COMPLETED | Mantle Cell Lymphoma |
Washington University School of Medicine |
2018-11-29 | PHASE2 |
| NCT03259529 | COMPLETED | Diffuse Large B Cell Lymphoma |
St. Petersburg State Pavlov Medical University |
2017-03-27 | PHASE1; PHASE2 |
| NCT02059239 | COMPLETED | Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma |
Weill Medical College of Cornell University |
2014-06-04 | PHASE1; PHASE2 |
| NCT02951156 | TERMINATED | Diffuse Large B-Cell Lymphoma |
Pfizer |
2016-12-16 | PHASE3 |
| NCT01216683 | COMPLETED | Lymphoma |
ECOG-ACRIN Cancer Research Group |
2011-02-09 | PHASE2 |
| NCT02836639 | UNKNOWN | Lymphoma, Non-Hodgkin |
Pusan National University Hospital |
2016-02 | PHASE2 |
| NCT02006485 | COMPLETED | Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma |
TG Therapeutics, Inc. |
2013-12-13 | PHASE1 |
| NCT02433795 | COMPLETED | Marginal Zone B-cell Lymphoma |
Seoul National University Hospital |
2015-05 | PHASE2 |
| NCT02499627 | TERMINATED | Lymphatic Diseases |
Fondazione Italiana Linfomi - ETS |
2015-12-23 | PHASE2 |
| NCT01569295 | COMPLETED | Chronic Lymphocytic Leukemia |
Gilead Sciences |
2012-06-15 | PHASE3 |
| NCT01889069 | COMPLETED | Lymphoma |
Hoffmann-La Roche |
2013-07-31 | PHASE3 |
| NCT00880815 | COMPLETED | CD20 Positive; Chronic Lymphocytic Leukemia; Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; T-Cell Non-Hodgkin Lymphoma |
M.D. Anderson Cancer Center |
2009-02-17 | PHASE1 |
| NCT01490723 | COMPLETED | Leukemia; Lymphoma |
M.D. Anderson Cancer Center |
2013-01 | PHASE2 |
| NCT02168140 | COMPLETED | Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia |
Wake Forest University Health Sciences |
2014-09 | PHASE1 |
| NCT03343652 | COMPLETED | Hodgkin's Lymphoma |
St. Petersburg State Pavlov Medical University |
2017-05-27 | PHASE1; PHASE2 |
| NCT02733042 | COMPLETED | Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Celgene |
2016-05-11 | PHASE1; PHASE2 |
| NCT02002598 | TERMINATED | Multiple Myeloma |
Suzanne Lentzsch, MD |
2013-11 | PHASE1; PHASE2 |
| NCT01222260 | COMPLETED | AL Amyloidosis |
Columbia University |
2013-01 | PHASE2 |
| NCT01535924 | COMPLETED | Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Recurrent Adult Hodgkin Lymphoma |
Beth Christian |
2012-02-09 | PHASE1; PHASE2 |
| NCT01611090 | COMPLETED | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Janssen Research & Development, LLC |
2012-09-19 | PHASE3 |
| NCT02728531 | COMPLETED | Mantle Cell Lymphoma |
Washington University School of Medicine |
2016-04-18 | PHASE1 |
| NCT02414568 | COMPLETED | Classical Hodgkin Lymphoma |
The Lymphoma Academic Research Organisation |
2015-07-17 | PHASE2 |
| NCT02148913 | COMPLETED | Multiple Myeloma |
Corewell Health West |
2014-06 | PHASE1 |
| NCT01649622 | WITHDRAWN | Leukemia; Lymphoma |
M.D. Anderson Cancer Center |
2012-12 | PHASE2 |
| NCT02071225 | COMPLETED | Chronic Lymphocytic Leukemia |
Hoffmann-La Roche |
2014-04-09 | PHASE2 |
| NCT02315157 | WITHDRAWN | Multiple Myeloma; Plasma Cell Leukemia |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2014-06 | PHASE1 |
| NCT02758925 | UNKNOWN | Diffuse Large B Cell Lymphoma |
University Hospital, Caen |
2016-06 | PHASE2 |
| NCT00899431 | TERMINATED | Chronic Lymphocytic Leukemia |
M.D. Anderson Cancer Center |
2009-05-06 | PHASE2 |
| NCT02237261 | COMPLETED | Multiple Myeloma |
University Hospital Heidelberg |
2014-11 | PHASE2 |
| NCT01458366 | COMPLETED | Non-Hodgkin's Lymphoma |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2011-11-09 | PHASE1; PHASE2 |
| NCT01671904 | COMPLETED | Chronic Lymphocytic Leukemia |
Genentech, Inc. |
2014-01-13 | PHASE1 |
| NCT01686321 | COMPLETED | Aggressive Lymphoma |
University of Göttingen |
2012-07-04 | PHASE2 |
| NCT01886872 | ACTIVE_NOT_RECRUITING | Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia |
National Cancer Institute (NCI) |
2014-01-15 | PHASE3 |
| NCT02753062 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Asan Medical Center |
2015-08 | PHASE2 |
| NCT01289223 | TERMINATED | Indolent B-cell NHL |
Mundipharma Research Limited |
2011-02 | PHASE3 |
| NCT02008006 | TERMINATED | Follicular Lymphoma |
Centre Leon Berard |
2014-07-09 | PHASE2 |
| NCT01657331 | COMPLETED | Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma |
Columbia University |
2012-07 | PHASE1; PHASE2 |
| NCT02477215 | COMPLETED | Multiple Myeloma |
Parameswaran Hari |
2015-10-09 | PHASE1; PHASE2 |
| NCT02596971 | COMPLETED | Diffuse Large B-Cell Lymphoma, Lymphoma Follicular |
Hoffmann-La Roche |
2015-12-22 | PHASE1; PHASE2 |
| NCT02240719 | COMPLETED | Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Multiple Myeloma |
University of California, Davis |
2014-10 | PHASE1 |
| NCT01891227 | COMPLETED | Breast Cancer |
Arbeitsgemeinschaft medikamentoese Tumortherapie |
2013-08-09 | PHASE2 |
| NCT01332617 | WITHDRAWN | Myeloma |
University of Louisville |
2011-04 | PHASE2 |
| NCT03392714 | UNKNOWN | PCNSL |
Chonnam National University Hospital |
2016-01-20 | PHASE2 |
| NCT01077518 | TERMINATED | Lymphoma, Follicular |
Novartis Pharmaceuticals |
2010-08-26 | PHASE3 |
| NCT02130869 | COMPLETED | Neuroblastoma; Lymphoma; High-risk Tumor |
St. Jude Children's Research Hospital |
2014-10-10 | PHASE1 |
| NCT01678430 | UNKNOWN | Chronic Lymphocytic Leukaemia |
University of Liverpool |
2011-12 | PHASE3 |
| NCT02320383 | UNKNOWN | Chronic Lymphocytic Leucemia |
Munich Municipal Hospital |
2014-11 | PHASE2 |
| NCT01177683 | TERMINATED | Multiple Myeloma |
Sherif Farag, MB, BS |
2010-07 | PHASE1; PHASE2 |
| NCT01400685 | COMPLETED | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; B Chronic Lymphocytic Leukemia |
Massachusetts General Hospital |
2012-12 | PHASE1 |
| NCT02371148 | COMPLETED | Waldenstrom's Macroglobulinemia |
Fondazione Italiana Linfomi - ETS |
2014-06 | PHASE2 |
| NCT01078142 | COMPLETED | Follicular Lymphoma; Mantle Cell Lymphoma |
Georg Hess, MD |
2010-02-02 | PHASE1; PHASE2 |
| NCT02424045 | COMPLETED | T-cell Lymphoma |
Samsung Medical Center |
2015-05 | PHASE2 |
| NCT02594163 | TERMINATED | Diffuse Large B-cell Lymphoma Refractory; Follicular B-cell Non-Hodgkin's Lymphoma |
Seagen Inc. |
2015-10 | PHASE2 |
| NCT00963534 | COMPLETED | Mantle Cell Lymphoma |
Lund University Hospital |
2009-09 | PHASE1; PHASE2 |
| NCT02689141 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2016-02-04 | PHASE2 |
| NCT02194374 | WITHDRAWN | Leukemia |
M.D. Anderson Cancer Center |
2015-01 | PHASE1 |
| NCT01650701 | COMPLETED | Follicular Lymphoma |
The Lymphoma Academic Research Organisation |
2012-02 | PHASE3 |
| NCT01286272 | COMPLETED | Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Grade 3 Follicular Lymphoma; Grade 3a Follicular Lymphoma |
National Cancer Institute (NCI) |
2011-04-28 | PHASE2 |
| NCT02623920 | WITHDRAWN | Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma; Grey Zone Lymphoma; High Grade B Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma |
University of Arizona |
2015-12-16 | PHASE2 |
| NCT02005471 | COMPLETED | Chronic Lymphocytic Leukemia |
Hoffmann-La Roche |
2014-03-17 | PHASE3 |
| NCT01096992 | COMPLETED | Leukemia |
M.D. Anderson Cancer Center |
2010-04-19 | PHASE1; PHASE2 |
| NCT02134262 | UNKNOWN | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
Jichi Medical University |
2014-05 | PHASE1; PHASE2 |
| NCT01905943 | COMPLETED | Chronic Lymphocytic Leukemia |
Hoffmann-La Roche |
2013-11-04 | PHASE3 |
| NCT01294579 | COMPLETED | Lymphoma, Non-Hodgkin |
Novartis Pharmaceuticals |
2011-05-17 | PHASE2 |
| NCT01754402 | UNKNOWN | Multiple Myeloma |
Cristina Gasparetto |
2013-01-07 | PHASE1; PHASE2 |
| NCT02689986 | COMPLETED | Cold Agglutinin Disease; Autoimmune Hemolytic Anemia |
Helse Fonna |
2013-01 | PHASE2 |
| NCT01491841 | COMPLETED | Non-Hodgkin's Lymphoma |
Anne Beaven, MD |
2011-11-01 | PHASE1 |
| NCT02320487 | COMPLETED | Chronic Lymphocytic Leukemia |
Genentech, Inc. |
2015-03-31 | PHASE2 |
| NCT02576275 | WITHDRAWN | Indolent Non-Hodgkin's Lymphoma; Follicular Lymphoma; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma |
SecuraBio |
2015-12 | PHASE3 |
| NCT02187861 | COMPLETED | Follicular Lymphoma |
Hoffmann-La Roche |
2014-12-01 | PHASE2 |
| NCT01626352 | COMPLETED | Diffuse Large B-Cell Lymphoma |
SCRI Development Innovations, LLC |
2012-10 | PHASE2 |
| NCT02345863 | COMPLETED | Chronic Lymphocytic Leucemia |
German CLL Study Group |
2015-01-16 | PHASE2 |
| NCT04569838 | COMPLETED | Indolent B-Cell Non-Hodgkin's Lymphomas |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2012-05 | PHASE2 |
| NCT02420210 | TERMINATED | Diffuse Large B-Cell Lymphoma |
University of Chicago |
2015-11 | PHASE2 |
| NCT01871675 | COMPLETED | Lymphoma; Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma; T-cell Lymphoma |
SCRI Development Innovations, LLC |
2013-05 | PHASE1 |
| NCT01980888 | TERMINATED | Chronic Lymphocytic Leukemia |
Gilead Sciences |
2014-02-05 | PHASE3 |
| NCT01732926 | TERMINATED | Indolent Non-Hodgkin's Lymphomas |
Gilead Sciences |
2013-01-02 | PHASE3 |
| NCT01900509 | COMPLETED | Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Acute Leukemia |
St. Jude Children's Research Hospital |
2013-08 | PHASE1 |
| NCT02224729 | COMPLETED | Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2014-08-25 | PHASE2 |
| NCT01352312 | TERMINATED | Chronic Lymphocytic Leukemia; B-Cell Non-Hodgkin's Lymphoma |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2011-05-25 | PHASE1 |
| NCT00916058 | COMPLETED | Multiple Myeloma |
Weill Medical College of Cornell University |
2009-04-23 | PHASE1; PHASE2 |
| NCT01332968 | COMPLETED | Non-Hodgkin's Lymphoma |
Hoffmann-La Roche |
2011-07-06 | PHASE3 |
| NCT01701076 | COMPLETED | Multiple Myeloma |
Cantonal Hospital of St. Gallen |
2012-03 | PHASE2 |
| NCT02423837 | UNKNOWN | Follicular Lymphoma |
National Research Center for Hematology, Russia |
2013-12 | PHASE3 |
| NCT01412879 | COMPLETED | Lymphoma |
SWOG Cancer Research Network |
2011-11 | PHASE2 |
| NCT01466153 | COMPLETED | Chronic Lymphocytic Leukemia (CLL) |
MedImmune LLC |
2012-02-07 | PHASE2 |
| NCT00901927 | TERMINATED | Follicular Lymphoma |
M.D. Anderson Cancer Center |
2009-05 | PHASE2 |
| NCT01874054 | COMPLETED | Hodgkin Disease |
Seagen Inc. |
2013-06 | PHASE1; PHASE2 |
| NCT01526694 | COMPLETED | Multiple Myeloma |
Azienda Ospedaliera di Bolzano |
2012-07 | PHASE2 |
| NCT00823797 | COMPLETED | Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Neoplasm |
University of Washington |
2008-10 | PHASE2 |
| NCT01612988 | TERMINATED | B-cell Chronic Lymphocytic Leukemia (B-CLL) |
French Innovative Leukemia Organisation |
2012-07 | PHASE2 |
| NCT01691807 | COMPLETED | Cancer |
Novartis Pharmaceuticals |
2013-01 | PHASE1 |
| NCT00705250 | COMPLETED | Hodgkin's Disease; Lymphoma |
Memorial Sloan Kettering Cancer Center |
2008-06 | PHASE2 |
| NCT00825149 | COMPLETED | Non-Hodgkin's Lymphoma |
Hoffmann-La Roche |
2009-02 | PHASE1 |
| NCT01296256 | COMPLETED | Bendamustine; Conditioning Therapy; Autologous Stem Cell Transplant; Aggressive Non Hodgkin's Lymphoma |
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
2011-05 | PHASE2 |
| NCT02056756 | COMPLETED | Multiple Myeloma |
Stichting European Myeloma Network |
2014-04 | PHASE1; PHASE2 |
| NCT01056276 | COMPLETED | Multiple Myeloma |
SCRI Development Innovations, LLC |
2010-05 | PHASE2 |
| NCT01412307 | UNKNOWN | Recurrent Adult Hodgkin Lymphoma |
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale |
2011-07 | PHASE1; PHASE2 |
| NCT01596621 | COMPLETED | Non-Hodgkin Lymphoma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2012-08-06 | PHASE3 |
| NCT01165112 | COMPLETED | Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma |
University of Washington |
2010-09 | PHASE1; PHASE2 |
| NCT00856830 | COMPLETED | Small Cell Lung Cancer; Extensive Stage Lung Cancer; Chemonaive |
University of Alabama at Birmingham |
2009-04 | PHASE1; PHASE2 |
| NCT01088048 | COMPLETED | Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma |
Gilead Sciences |
2010-03-25 | PHASE1 |
| NCT01832922 | COMPLETED | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Dartmouth-Hitchcock Medical Center |
2013-04 | PHASE1 |
| NCT01326702 | COMPLETED | Adult B Acute Lymphoblastic Leukemia; Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Adult Solid Neoplasm; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Chronic Lymphocytic Leukemia; Cutaneous B-Cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Hepatosplenic T-Cell Lymphoma; Intraocular Lymphoma; Lymphomatous Involvement of Non-Cutaneous Extranodal Site; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Nodal Marginal Zone Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides and Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Plasma Cell Myeloma; Small Intestinal Lymphoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia |
National Cancer Institute (NCI) |
2011-07 | PHASE1; PHASE2 |
| NCT02168907 | TERMINATED | B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenström Macroglobulinemia |
Wake Forest University Health Sciences |
2014-12 | PHASE1 |
| NCT01661881 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma |
Christine Ryan |
2012-08-16 | PHASE2 |
| NCT00837928 | COMPLETED | Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
John Grecula |
2009-02-19 | PHASE1 |
| NCT01523860 | COMPLETED | Follicular Lymphoma |
Fondazione Italiana Linfomi - ETS |
2009-06 | PHASE2 |
| NCT01724021 | COMPLETED | Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma |
Hoffmann-La Roche |
2012-12 | PHASE3 |
| NCT01188681 | COMPLETED | Chronic Lymphocytic Leukemia (CLL) |
Aptevo Therapeutics |
2010-09 | PHASE1; PHASE2 |
| NCT01486797 | COMPLETED | Chronic Lymphocytic Leukemia |
TME Pharma AG |
2012-03 | PHASE2 |
| NCT01429025 | COMPLETED | Refractory/Relapsed Indolent Non-Hodgkin Lymphoma |
Alliance for Clinical Trials in Oncology |
2012-05 | PHASE1 |
| NCT02162888 | COMPLETED | Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate |
Eagle Pharmaceuticals, Inc. |
2013-11 | PHASE1 |
| NCT00864942 | COMPLETED | Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma |
Georgetown University |
2009-02 | PHASE1 |
| NCT01029730 | COMPLETED | Lymphoma |
SCRI Development Innovations, LLC |
2010-03 | PHASE2 |
| NCT01059630 | COMPLETED | Non-Hodgkin's Lymphoma |
Genentech, Inc. |
2010-04-30 | PHASE3 |
| NCT01754870 | WITHDRAWN | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) |
University of Wisconsin, Madison |
2013-11 | PHASE2 |
| NCT01662050 | COMPLETED | Mantle Cell Lymphoma |
Fondazione Italiana Linfomi - ETS |
2012-03-20 | PHASE2 |
| NCT01884441 | UNKNOWN | Hodgkin's Lymphoma |
Armando Santoro, MD |
2011-07 | PHASE2 |
| NCT01737177 | COMPLETED | Mantle Cell Lymphoma |
Fondazione Italiana Linfomi - ETS |
2012-07-31 | PHASE2 |
| NCT01244451 | COMPLETED | Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or; Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2010-12 | PHASE2 |
| NCT01484626 | TERMINATED | Multiple Myeloma |
Loyola University |
2011-05-05 | PHASE1; PHASE2 |
| NCT01376401 | COMPLETED | Multiple Myeloma |
PETHEMA Foundation |
2011-07 | PHASE2 |
| NCT01152203 | COMPLETED | Advanced Cancer |
M.D. Anderson Cancer Center |
2010-06 | PHASE1 |
| NCT01010568 | TERMINATED | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Georgetown University |
2010-04 | PHASE2 |
| NCT01410513 | COMPLETED | Indolent Non-Hodgkin Lymphoma; Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia |
Sanofi |
2011-12 | PHASE1 |
| NCT00987493 | COMPLETED | Lymphoma |
Swiss Cancer Institute |
2009-09 | PHASE1; PHASE2 |
| NCT01022021 | COMPLETED | Lymphoma |
University of Kansas Medical Center |
2010-01 | EARLY_PHASE1 |
| NCT01232556 | TERMINATED | Lymphoma, Non-Hodgkin |
Pfizer |
2011-04-04 | PHASE3 |
| NCT01056510 | COMPLETED | Lymphocytic Leukemia, Chronic |
Hoffmann-La Roche |
2010-03 | PHASE4 |
| NCT01369849 | COMPLETED | Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia |
National Cancer Institute (NCI) |
2011-09 | PHASE1; PHASE2 |
| NCT01315873 | TERMINATED | Multiple Myeloma |
NYU Langone Health |
2011-09 | PHASE2 |
| NCT01423539 | WITHDRAWN | Diffuse Large B-Cell Lymphoma |
Genentech, Inc. |
2011-10 | PHASE2 |
| NCT01990144 | UNKNOWN | Diffuse Large B-cell Lymphoma |
Fondazione Italiana Linfomi - ETS |
2011-11 | PHASE2 |
| NCT01234467 | COMPLETED | Diffuse Large B-Cell Lymphoma; Lymphoma, Diffuse Large-Cell; Diffuse Large-Cell Lymphoma; Lymphoma |
UNC Lineberger Comprehensive Cancer Center |
2011-03 | PHASE2 |
| NCT01127841 | UNKNOWN | Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line. |
Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas |
2009-07 | PHASE2 |
| NCT01015248 | COMPLETED | MALT LYMPHOMA |
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
2009-05 | PHASE2 |
| NCT01133158 | COMPLETED | Non-Hodgkin's Lymphoma |
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
2009-07 | PHASE2 |
| NCT01465230 | TERMINATED | Chronic Lymphocytic Leukemia |
Yale University |
2012-03 | PHASE2 |
| NCT01110135 | COMPLETED | Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Multiple Myeloma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia |
University of Washington |
2010-08 | PHASE2 |
| NCT01558167 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2011-02 | PHASE1; PHASE2 |
| NCT01657955 | UNKNOWN | Chronic Lymphocytic Leukemia; Leukemia; Neoplasms |
Shandong Lanjin Pharmaceuticals Co.,Ltd |
2011-01 | PHASE3 |
| NCT00834678 | COMPLETED | Breast Cancer |
Ohio State University Comprehensive Cancer Center |
2009-04 | PHASE1; PHASE2 |
| NCT00831597 | COMPLETED | Diffuse Large B-Cell Lymphoma |
Pharmatech |
2008-11 | PHASE2 |
| NCT01831505 | COMPLETED | Lymphoma |
Presage Biosciences |
2012-11 | PHASE1 |
| NCT00974233 | COMPLETED | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
University of Wisconsin, Madison |
2009-10 | PHASE2 |
| NCT01109264 | COMPLETED | Chronic Lymphocytic Leukemia |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2010-03 | PHASE2 |
| NCT01500083 | COMPLETED | Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia |
Lundbeck Canada Inc. |
2012-03 | PHASE3 |
| NCT01168804 | COMPLETED | Multiple Myeloma |
Austrian Forum Against Cancer |
2010-06 | PHASE2 |
| NCT00868413 | COMPLETED | Chronic Lymphocytic Leukemia |
AbbVie (prior sponsor, Abbott) |
2009-11 | PHASE1 |
| NCT01317901 | COMPLETED | B-cell Small Lymphocytic Lymphoma Recurrent |
Aptevo Therapeutics |
2011-05 | PHASE1 |
| NCT01045681 | COMPLETED | Multiple Myeloma |
Intergroupe Francophone du Myelome |
2010-03-03 | PHASE2 |
| NCT01520922 | COMPLETED | Chronic Lymphocytic Leukemia (CLL); Leukaemia, Lymphocytic, Chronic |
Novartis Pharmaceuticals |
2012-03 | PHASE2 |
| NCT01300247 | COMPLETED | Lymphocytic Leukemia, Chronic |
Genentech, Inc. |
2011-05 | PHASE1 |
| NCT00879073 | TERMINATED | Brain Metastases |
H. Lee Moffitt Cancer Center and Research Institute |
2009-04 | PHASE1 |
| NCT01049945 | COMPLETED | Refractory Multiple Myeloma |
Mayo Clinic |
2010-02 | PHASE1; PHASE2 |
| NCT01141725 | COMPLETED | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); de Novo Myelodysplastic Syndromes; Myelodysplastic Syndrome With Isolated Del(5q); Untreated Adult Acute Myeloid Leukemia |
Fred Hutchinson Cancer Center |
2010-09 | PHASE1; PHASE2 |
| NCT01002703 | UNKNOWN | Multiple Myeloma |
University of Leipzig |
2009-09 | PHASE1; PHASE2 |
| NCT01313611 | TERMINATED | Follicular Lymphoma |
The Lymphoma Academic Research Organisation |
2011-02 | PHASE2 |
| NCT00947388 | TERMINATED | Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma |
Case Comprehensive Cancer Center |
2008-11 | PHASE1 |
| NCT00984542 | COMPLETED | Lung Cancer |
Vanderbilt-Ingram Cancer Center |
2009-09 | PHASE2 |
| NCT01570049 | UNKNOWN | Non-Hodgkin Lymphoma by Clinical Course |
Shandong Lanjin Pharmaceuticals Co.,Ltd |
2010-04 | PHASE3 |
| NCT00951457 | COMPLETED | Leukemia, Lymphocytic, Chronic, B-Cell |
Arbeitsgemeinschaft medikamentoese Tumortherapie |
2009-03 | PHASE1; PHASE2 |
| NCT01073163 | COMPLETED | Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma |
Cephalon |
2010-02 | PHASE3 |
| NCT01275209 | COMPLETED | Follicular Lymphoma |
Novartis Pharmaceuticals |
2011-02 | PHASE1 |
| NCT01686386 | UNKNOWN | Multiple Myeloma |
Gruppo Italiano Studio Linfomi |
2010-02 | PHASE1; PHASE2 |
| NCT01238146 | WITHDRAWN | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma |
National Cancer Institute (NCI) |
2010-10 | PHASE1; PHASE2 |
| NCT01170052 | WITHDRAWN | Mantle Cell Lymphoma |
Charite University, Berlin, Germany |
2010-05 | PHASE1; PHASE2 |
| NCT01221103 | UNKNOWN | Lymphoma, Mantle-Cell |
Southern Europe New Drug Organization |
2010-04 | PHASE1; PHASE2 |
| NCT00877006 | COMPLETED | Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2009-04-30 | PHASE3 |
| NCT00790855 | TERMINATED | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia |
M.D. Anderson Cancer Center |
2008-11 | PHASE1; PHASE2 |
| NCT01929265 | COMPLETED | Indolent Non-follicular; Non-Hodgkin's Lymphoma |
Fondazione Italiana Linfomi - ETS |
2011-01 | PHASE2 |
| NCT00867503 | COMPLETED | Ovarian Cancer |
University of Arizona |
2009-02 | PHASE2 |
| NCT00891839 | COMPLETED | Mantle Cell Lymphoma |
Cephalon |
2009-06 | PHASE2 |
| NCT00872976 | WITHDRAWN | Chronic Lymphocytic Leukemia |
Bristol-Myers Squibb |
2009-05 | PHASE1 |
| NCT01179490 | TERMINATED | Multiple Myeloma |
SymBio Pharmaceuticals |
2010-09 | PHASE2 |
| NCT01088984 | COMPLETED | Leukemia |
Teva Branded Pharmaceutical Products R&D, Inc. |
2010-08 | PHASE1; PHASE2 |
| NCT00920855 | COMPLETED | Multiple Myeloma |
Cephalon |
2009-06 | PHASE1; PHASE2 |
| NCT01108341 | COMPLETED | Non-Hodgkin's Lymphoma (NHL) |
Cephalon |
2010-05 | PHASE2 |
| NCT00769522 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2008-10-02 | PHASE3 |
| NCT00959686 | COMPLETED | T-cell Lymphoma |
French Innovative Leukemia Organisation |
2009-09 | PHASE2 |
| NCT00992134 | COMPLETED | Lymphoma, Mantle-Cell |
St. Bortolo Hospital |
2009-06 | PHASE2 |
| NCT00740415 | COMPLETED | Lymphoma |
French Innovative Leukemia Organisation |
2007-06 | PHASE2 |
| NCT01042704 | COMPLETED | Myeloma |
Robert Redner, MD |
2008-02 | PHASE1 |
| NCT00661739 | COMPLETED | Metastatic Breast Cancer |
GBG Forschungs GmbH |
2005-07 | PHASE1 |
| NCT00939328 | WITHDRAWN | Leukemia |
SWOG Cancer Research Network |
2009-09 | PHASE2 |
| NCT01456351 | COMPLETED | Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma |
University of Giessen |
2003-09 | PHASE3 |
| NCT01125787 | TERMINATED | Chronic Lymphocytic Leukemia (CLL) |
Nevada Cancer Institute |
2010-05 | PHASE2 |
| NCT00758693 | WITHDRAWN | Chronic Lymphocytic Leukemia |
University of Kentucky |
2008-10 | PHASE2 |
| NCT00636792 | COMPLETED | Follicular Lymphoma |
Millennium Pharmaceuticals, Inc. |
2008-02 | PHASE2 |
| NCT00863850 | COMPLETED | Malignancy |
Cephalon |
2009-05 | PHASE1 |
| NCT00634881 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2003-11 | PHASE1; PHASE2 |
| NCT00612183 | COMPLETED | Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma |
SymBio Pharmaceuticals |
2007-12 | PHASE2 |
| NCT00991211 | COMPLETED | Non-Hodgkin Lymphomas; Follicular Lymphomas; Immunocytomas; Lymphocytic Lymphomas; Marginal Zone Lymphomas |
University of Giessen |
2004-01 | PHASE3 |
| NCT00547534 | COMPLETED | Non-Hodgkin's Lymphoma |
University of Rochester |
2007-10 | PHASE2 |
| NCT01423032 | COMPLETED | Chronic Lymphocytic Leukemia |
WiSP Wissenschaftlicher Service Pharma GmbH |
2001-09 | PHASE2; PHASE3 |
| NCT00426855 | COMPLETED | Lymphoma, Non-Hodgkin |
Peter Moosmann |
2007-01 | PHASE1; PHASE2 |
| NCT00274989 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2005-11 | PHASE2 |
| NCT00274963 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2004-10 | PHASE2 |
| NCT00389051 | COMPLETED | Non-Hodgkin's Lymphoma |
SymBio Pharmaceuticals |
2006-10-31 | PHASE1 |
| NCT00139841 | COMPLETED | Non-Hodgkin's Lymphoma |
Cephalon |
2005-10 | PHASE3 |
| NCT00069758 | COMPLETED | Non-Hodgkin's Lymphoma |
Cephalon |
2003-09 | PHASE2 |
| NCT00076349 | COMPLETED | Non-Hodgkin's Lymphoma |
Cephalon |
2004-04 | PHASE2 |
| NCT01131247 | WITHDRAWN | Chronic Lymphocytic Leukemia (CLL) |
Nevada Cancer Institute |
PHASE2 | |
| NCT00385125 | UNKNOWN | Lymphoma, High-Grade |
University of Magdeburg |
2004-08 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-02-13)
Check the
Bendamustine
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.